Clin2
NCT06862726Likely a fitEnrolling by invitation

Comparing two blood thinners for atrial fibrillation

Non Valvular Atrial Fibrillation

Part of Heart & circulation clinical trials.

This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
120 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have been diagnosed with atrial fibrillation (an irregular heart rhythm)
  • You are willing to sign a consent form to join the study
  • You are not currently taking certain other medications (like some antifungals, HIV meds, or seizure meds) in the last 14 days
  • You are not pregnant or breastfeeding

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04642430Recruiting· Phase 4
Test of blood thinners comparing rivaroxaban vs apixaban

This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.

Victoria, British Columbia
NCT06953726Recruiting· Phase 4
Comparing apixaban and rivaroxaban for atrial fibrillation

This study compares two common blood thinners, apixaban and rivaroxaban, in veterans with atrial fibrillation or flutter to see which one is safer and works better. If you are already taking one of these medicines, you may be able to join.

Miami, Florida
NCT07753200Recruiting· Phase 4
Comparing two blood thinners for atrial fibrillation and heart disease

This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.

Seoul
NCT06187311Recruiting· Phase 4
Rivaroxaban for atrial fibrillation patients

This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.

Seoul
NCT06864052Not yet recruiting
Comparing two blood thinners after stroke with atrial fibrillation

This trial is testing two blood thinners (edoxaban and apixaban) to see how they compare in preventing new brain spots on MRI after a stroke in people with atrial fibrillation. It may help you and your doctor choose the safer option.

Seoul, Seoul
NCT06531122Recruiting· Phase 3
Comparing two blood thinners for cerebral venous thrombosis

This trial compares two blood thinners, Rivaroxaban and Apixaban, to see which works better for people with a blood clot in a brain vein. It may help find the safest and most effective treatment for this condition.

Kafr ash Shaykh

Hear when a new Non Valvular Atrial Fibrillation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.